Wholesale Drug Distributor Executives Sentenced in $92M HIV Drug Black Market Scheme

Two executives from Donor Related Services LLC, a New Jersey-based wholesale drug distributor, were sentenced to federal prison on January 9, 2025 for operating a scheme that trafficked at least $92 million in counterfeit and diverted HIV medications through the U.S. pharmaceutical supply chain. The case demonstrates how wholesale drug distribution compliance failures enabled systematic pharmaceutical wholesale fraud across multiple state jurisdictions.

Regulatory Context: PDMA and State Licensure Requirements

Wholesale drug distributors operate under the Prescription Drug Marketing Act of 1987 (21 U.S.C. § 353), which established pedigree requirements for prescription drugs moving through wholesale channels. Under 21 CFR Part 203, wholesale distributors must maintain records documenting each prior sale, purchase, or trade of a drug, creating an auditable chain of custody from manufacturer to dispenser.

State boards of pharmacy separately license wholesale drug distributors under state-specific statutes that typically require:

• Designated representative responsible for regulatory compliance
• Physical inspection of facilities
• Annual license renewal with updated operational information
• Immediate reporting of adverse events, recalls, or suspected counterfeits

The Drug Supply Chain Security Act (DSCSA), enacted in 2013, established additional transaction documentation requirements that took full effect for wholesale distributors on November 27, 2023. DSCSA requires verification of authorized trading partners and maintenance of transaction information, transaction history, and transaction statements (TI/TH/TS) for all product movements.

Criminal Scheme Details

Between 2014 and 2019, Donor Related Services executives Robert Gentry (sentenced to 90 months) and Armando Herrera (sentenced to 72 months) purchased HIV medications from individuals who acquired them through fraudulent means, including:

• Medications obtained using stolen patient identities and fake prescriptions
• Drugs diverted from AIDS service organizations and patient assistance programs
• Products lacking verifiable pedigree documentation required under federal law

The executives resold these drugs to licensed pharmacies and other wholesale distributors at below-market prices. Court documents indicate the scheme involved products intended for vulnerable patient populations, routed through distribution channels that bypassed standard verification protocols.

According to the U.S. Attorney's Office for the District of New Jersey, both defendants failed to maintain required pedigree documentation and knowingly falsified wholesale distribution records to conceal the illicit sourcing of products.

Compliance Breakdown Analysis

This case illustrates four critical failure points in wholesale drug distribution compliance:

1. Trading Partner Verification Failures

Downstream purchasers did not adequately verify that Donor Related Services maintained legitimate product sourcing. Under DSCSA, wholesale distributors must verify that their trading partners are "authorized" — meaning properly licensed and registered. Below-market pricing should trigger enhanced due diligence.

2. Pedigree Documentation Gaps

The absence of complete pedigree records — documenting each prior transaction from manufacturer forward — enabled counterfeit products to enter legitimate supply chains. State pharmacy boards require maintenance of these records for inspection.

3. Suspicious Order Monitoring

The volume of HIV medications moving through a single wholesale distributor, particularly at discounted pricing, represents a compliance red flag that should trigger investigation under standard quality management systems.

4. State Board Reporting Obligations

New Jersey's wholesale drug distributor licensing statute (N.J.S.A. 24:6B-1 et seq.) requires immediate notification to the State Board of Pharmacy of any suspected counterfeit drugs. The defendants did not self-report their activities despite handling products with questionable provenance.

Operational Impact for Wholesale Distributors

This enforcement action reinforces FDA and state board expectations for wholesale drug distributor due diligence:

• Enhanced trading partner qualification: Below-market pricing or unfamiliar suppliers require documented verification beyond basic license checks
• Physical inspection protocols: Visual verification of product integrity, packaging consistency, and serialization data (post-DSCSA)
• Designated representative accountability: The responsible party faces potential criminal liability for compliance failures, not just civil penalties
• Suspicious activity reporting: Distributors must establish internal thresholds for escalating concerns to legal counsel and regulatory authorities

The sentences (90 and 72 months, plus restitution) exceed typical civil enforcement outcomes, signaling DOJ's willingness to pursue criminal charges in cases involving intentional fraud beyond negligent recordkeeping.

What ColdChainCheck Data Shows

ColdChainCheck tracks 1,275 wholesale drug distributors, 3PLs, and cold chain logistics providers across 51 jurisdictions. The compliance score distribution reveals that 919 entities (72%) fall into the "Fair" tier (40-59 points), indicating partial compliance signals verified across multiple data sources. Only 28 entities (2%) achieve "Excellent" scores (80-100 points) with comprehensive verification across state licensure, NABP accreditation, FDA registration, and clean enforcement records.

Donor Related Services LLC held active New Jersey wholesale drug distributor licenses during the period of criminal activity (2014-2019). The case illustrates why license status alone provides insufficient due diligence. A distributor can maintain active state licensure while simultaneously operating fraudulent procurement schemes — regulatory databases reflect license issuance, not ongoing operational compliance.

Of the 1,275 entities in ColdChainCheck's directory, 73 have at least one FDA recall, warning letter, or enforcement action on record. This represents 5.7% of tracked entities. These negative compliance signals — when cross-referenced with state licensing data and NABP accreditation status — provide a more complete compliance posture than any single data source.

Practical Due Diligence Steps

QA managers and compliance officers should implement the following in response to this enforcement action:

• Verify trading partner compliance scores before purchase orders: Use ColdChainCheck's directory to cross-reference state licenses, FDA registration, and NABP accreditation status for all wholesale suppliers. Entities scoring below 40 (Poor/Minimal tiers) require enhanced documentation review.

• Flag below-market pricing for quality review: Establish internal protocols requiring quality unit sign-off on any purchase 15%+ below average acquisition cost. Document the rationale for accepting discounted products in batch records.

• Audit pedigree documentation quarterly: Select 10-15 high-value or controlled substance SKUs per quarter and trace full transaction history back to manufacturer. Gaps in TI/TH/TS documentation under DSCSA should trigger trading partner suspension.

• Cross-reference enforcement databases monthly: ColdChainCheck tracks FDA warning letters, recalls, and state board actions. Set calendar reminders to verify that current suppliers maintain clean enforcement records. New actions should prompt immediate supplier questionnaires.

For detailed guidance on wholesale distributor qualification requirements, see ColdChainCheck's DSCSA compliance guide and state licensing requirement breakdown.

Disclaimer: This article provides informational content based on publicly available enforcement data and regulatory requirements. It does not constitute legal advice. Consult qualified legal counsel and regulatory affairs professionals for compliance guidance specific to your operations.